SunBio KRX:067370KOSDAQ
선바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, SunBio reported revenue of ₩2.2bn, up 29.9% year on year, and operating profit of ₩284m. SunBio (선바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
SunBio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.2bn | +29.9% | ₩284m margin 12.7% | ₩631m |
| Q1 2026 | ₩1.3bn | -57.4% | ₩458m margin 35.5% | ₩318m |
| Q4 2025 derived | ₩4.7bn | +38.3% | ₩2.1bn margin 45.0% | ₩2.1bn |
| Q3 2025 | ₩4.2bn | +132.8% | ₩1.6bn margin 38.2% | ₩1.3bn |
| Q2 2025 | ₩1.7bn | +8.2% | ₩118m margin 6.9% | −₩1.2bn |
| Q1 2025 | ₩3.0bn | +60.4% | ₩1.2bn margin 39.3% | ₩616m |
| Q4 2024 derived | ₩3.4bn | +22.6% | ₩1.5bn margin 45.6% | ₩1.6bn |
| Q3 2024 | ₩1.8bn | -53.9% | −₩142m margin −7.8% | −₩469m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
SunBio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest SunBio news Korean headlines
No articles yet.